Taiho, Servier deal

Taiho granted Servier exclusive rights to develop and commercialize TAS-102 in Europe and undisclosed countries. Taiho retains rights to the oral combination of trifluridine (FTD), an antineoplastic nucleoside analog, and tipiracil, an inhibitor of the FTD-degrading enzyme thymidine phosphorylase, in North America and Asia. ...